Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (131-140 of 327) with videos related to

Pageof 33
Sort By:
The Oncologist|May 7, 2017
Impact of Age on Outcomes with Immunotherapy for Patients with MelanomaAllison S Betof, Ryan D Nipp, Anita Giobbie-Hurder, et al.
Kidney International Reports|December 19, 2022
Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for MelanomaQiyu Wang, Ian A Strohbehn, Sophia Zhao, et al.
Cancer Research Communications|November 6, 2023
Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and TrametinibPaul B Chapman, Mark Klang, Michael A Postow, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 16, 2016
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF InhibitionDouglas B Johnson, Eirini Pectasides, Emily Feld, et al.
The Oncologist|May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaRyan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
Urologic Oncology|January 8, 2016
Primary genitourinary melanoma: Epidemiology and disease-specific survival in a large population-based cohortAlejandro Sanchez, Dayron Rodríguez, Christopher B Allard, et al.
Investigational New Drugs|May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 studyStergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Nature Medicine|October 19, 2018
Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanomaNoam Auslander, Gao Zhang, Joo Sang Lee, et al.
Melanoma Research|October 31, 2018
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter studyJoshua Z Drago, Donald Lawrence, Elisabeth Livingstone, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 24, 2012
Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2Richard W Joseph, Jeanette E Eckel-Passow, Ruchi Sharma, et al.
Pageof 33

Showing results (131-140 of 327) with videos related to

Sort By:
Pageof 33
The Oncologist|May 7, 2017
Impact of Age on Outcomes with Immunotherapy for Patients with MelanomaAllison S Betof, Ryan D Nipp, Anita Giobbie-Hurder, et al.
Kidney International Reports|December 19, 2022
Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for MelanomaQiyu Wang, Ian A Strohbehn, Sophia Zhao, et al.
Cancer Research Communications|November 6, 2023
Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and TrametinibPaul B Chapman, Mark Klang, Michael A Postow, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 16, 2016
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF InhibitionDouglas B Johnson, Eirini Pectasides, Emily Feld, et al.
The Oncologist|May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaRyan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
Urologic Oncology|January 8, 2016
Primary genitourinary melanoma: Epidemiology and disease-specific survival in a large population-based cohortAlejandro Sanchez, Dayron Rodríguez, Christopher B Allard, et al.
Investigational New Drugs|May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 studyStergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Nature Medicine|October 19, 2018
Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanomaNoam Auslander, Gao Zhang, Joo Sang Lee, et al.
Melanoma Research|October 31, 2018
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter studyJoshua Z Drago, Donald Lawrence, Elisabeth Livingstone, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 24, 2012
Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2Richard W Joseph, Jeanette E Eckel-Passow, Ruchi Sharma, et al.
Pageof 33